Cargando…
The Brown University Oncology Group Experience With FOLFOX + Nab-paclitaxel [FOLFOX-A] for Metastatic and Locally Advanced Pancreatic, BrUOG-292 and BrUOG-318
To evaluate response rate, toxicity, and efficacy of the novel combination of nab-paclitaxel, oxaliplatin, 5-fluorouracil, and leucovorin [FOLFOX-A] in patients with advanced pancreatic ductal adenocarcinoma [PDAC]. METHODS: BrUOG-292 and BrUOG-318 were two concurrently run, prospective, single-arm...
Autores principales: | Breakstone, Rimini, Almhanna, Khaldoun, Raufi, Alexander, Beard, Rachel E., Leonard, Kara-Lynne, Renaud, Jennifer, Kastura, Michaela, Dionson, Sopha, Wood, Roxanne, Sturtevant, Ashlee, Dipetrillo, Thomas, Olszewski, Adam, Safran, Howard |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9311474/ https://www.ncbi.nlm.nih.gov/pubmed/35749747 http://dx.doi.org/10.1097/COC.0000000000000928 |
Ejemplares similares
-
Cediranib with mFOLFOX6 vs bevacizumab with mFOLFOX6 in previously treated metastatic colorectal cancer
por: Cunningham, D, et al.
Publicado: (2013) -
Folfox encephalopathy: A rare case series
por: Batra, Ullas, et al.
Publicado: (2017) -
Cost-effectiveness of FOLFOX6+Bevacizumab Versus FOLFOX6+Cetuximab in Stage IV Colorectal Cancer Patients in Shiraz, Iran
por: Jafari, Abdosaleh, et al.
Publicado: (2023) -
Adjuvant Chemotherapy Using the FOLFOX Regimen in Colon Cancer
por: Jeon, Hyeong-Joon, et al.
Publicado: (2011) -
Posterior Reversible Encephalopathy Syndrome Associated with FOLFOX Chemotherapy
por: Porcello Marrone, Luiz Carlos, et al.
Publicado: (2013)